New diabetes drug BGM0504 takes on semaglutide in major trial
NCT ID NCT07064486
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial compares a new injectable drug, BGM0504, to the established drug semaglutide (Ozempic) in 477 adults with type 2 diabetes. All participants also take metformin. The study measures how well each drug controls blood sugar and weight over 24 weeks. The goal is to see if BGM0504 is a safe and effective alternative.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BGM0504 (a new injectable drug for diabetes)
What this could lead to
If successful, BGM0504 could offer a new once-weekly option to help control blood sugar and weight in people with type 2 diabetes.
What could go wrong
This is an early-phase 3 trial, so results may not confirm superiority over semaglutide. Side effects and long-term safety are still being studied.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES (T2DM) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
RS Universitas Indonesia
RECRUITINGDepok, West Java, Indonesia
-
RSUP Fatmawati
RECRUITINGJakarta, Indonesia
-
RSUP Persahabatan
RECRUITINGJakarta, Indonesia
-
RSUPN Dr. Cipto Mangunkusumo
RECRUITINGJakarta, Indonesia